|
PART I Pediatric Acute Care |
|
|
|
|
3 | (16) |
|
|
|
19 | (8) |
|
|
|
|
27 | (34) |
|
|
4 Trauma, Burns, and Common Critical Care Emergencies |
|
|
61 | (30) |
|
|
PART II Diagnostic and Therapeutic Information |
|
|
|
|
91 | (20) |
|
|
6 Analgesia and Procedural Sedation |
|
|
111 | (16) |
|
|
|
127 | (45) |
|
|
|
|
172 | (23) |
|
|
9 Development, Behavior, and Mental Health |
|
|
195 | (19) |
|
|
|
214 | (32) |
|
|
11 Fluids and Electrolytes |
|
|
246 | (22) |
|
|
|
268 | (16) |
|
|
13 Genetics: Metabolism and Dysmorphology |
|
|
284 | (21) |
|
|
|
305 | (29) |
|
|
|
15 Immunology and Allergy |
|
|
334 | (16) |
|
|
|
350 | (30) |
|
|
17 Microbiology and Infectious Disease |
|
|
380 | (35) |
|
|
|
|
415 | (23) |
|
|
|
438 | (29) |
|
|
|
467 | (18) |
|
|
|
485 | (38) |
|
|
|
|
523 | (17) |
|
|
|
540 | (9) |
|
|
|
549 | (23) |
|
|
|
572 | (30) |
|
|
|
602 | (19) |
|
|
|
|
27 Blood Chemistries and Body Fluids |
|
|
621 | (13) |
|
|
|
28 Biostatistics and Evidence-Based Medicine |
|
|
634 | (11) |
|
|
|
|
|
645 | (342) |
|
|
|
|
|
987 | (7) |
|
|
|
31 Drugs in Renal Failure |
|
|
994 | |
|
|
Notes and Abbreviations Used in Tables |
|
xiii | |
|
1 Infectious Agents and Drugs of Choice |
|
|
1 | (122) |
|
|
|
I Recommended Treatment for Bacterial Infections |
|
|
2 | (42) |
|
II Recommended Treatment for Mycobacterial Infections |
|
|
44 | (7) |
|
III Recommended Treatment for Viral Infections |
|
|
51 | (5) |
|
IV Recommended Treatment for Fungal Infections |
|
|
56 | (23) |
|
V Recommended Treatment for Parasitic and Protozoal Infections |
|
|
79 | (44) |
|
2 Recommended Empiric Antimicrobial Therapy for Selected Clinical Syndromes |
|
|
123 | (43) |
|
|
|
|
3 Drug Dosing in Special Circumstances |
|
|
166 | (77) |
|
|
|
|
I General Pediatric Drug Dosing |
|
|
166 | (2) |
|
II Developmental Dosing Considerations (Developmental Pharmacology) |
|
|
168 | (2) |
|
III Drug Dosing in Renal Insufficiency |
|
|
170 | (19) |
|
IV Drug Dosing in Hepatic Insufficiency |
|
|
189 | (14) |
|
|
203 | (9) |
|
VI Antimicrobial Tissue Distribution by Key Organ Systems |
|
|
212 | (31) |
|
4 Mechanisms of Action and Routes of Administration of Antimicrobial Agents |
|
|
243 | (9) |
|
|
5 Mechanisms of Drug Resistance |
|
|
252 | (5) |
|
|
I Common Mechanisms of Microbial Resistance |
|
|
253 | (2) |
|
II Discordance Between In Vitro Susceptibility and In Vivo Efficacy |
|
|
255 | (2) |
|
6 Therapeutic Drug Monitoring |
|
|
257 | (56) |
|
|
|
|
257 | (3) |
|
II Antimicrobials that Require Therapeutic Drug Monitoring |
|
|
260 | (4) |
|
III Special Topics in Antimicrobial Therapeutic Drug Monitoring |
|
|
264 | (2) |
|
IV Pharmacokinetic Monitoring in Therapeutic Drug Monitoring |
|
|
266 | (4) |
|
V Pharmacokinetics/Pharmacodynamics Antimicrobial Relationships |
|
|
270 | (2) |
|
|
272 | (41) |
|
|
313 | (20) |
|
|
|
|
314 | (1) |
|
|
315 | (1) |
|
III Central Nervous System |
|
|
316 | (4) |
|
|
320 | (2) |
|
|
322 | (4) |
|
|
326 | (1) |
|
|
327 | (1) |
|
|
328 | (1) |
|
|
329 | (1) |
|
|
330 | (1) |
|
|
330 | (1) |
|
|
331 | (1) |
|
|
331 | (2) |
|
8 Recommended Antimicrobial Prophylaxis for Selected Infectious Agents and Conditions |
|
|
333 | (16) |
|
|
|
9 Antimicrobial Desensitization Protocols |
|
|
349 | (13) |
|
|
|
|
349 | (2) |
|
|
351 | (1) |
|
|
352 | (1) |
|
IV Trimethoprim/Sulfamethoxazole (TMP/SMX) Oral |
|
|
353 | (1) |
|
|
354 | (1) |
|
|
355 | (2) |
|
|
357 | (2) |
|
|
359 | (1) |
|
|
359 | (1) |
|
|
359 | (3) |
|
|
362 | (209) |
|
|
|
362 | (2) |
|
|
364 | (1) |
|
III Explanation of Breast-Feeding Categories |
|
|
365 | (1) |
|
IV Explanation of Pregnancy Categories |
|
|
365 | (1) |
|
|
366 | (205) |
Index |
|
571 | |